Pharmacokinetic study with synthetic salmon calcitonin (Sandoz).
18 patients randomly divided into 3 groups of six each received 35 mug (140 M.R.C. Units) of synthetic salmon calcitonin intravenously, intramuscularly or subcutaneously. Plasma and urin concentrations were determined using the radioimmunoassay method. There was a rapid distribution phase of ca. 12 minutes after intravenous injection then an elimination half-life of 1.1 hours. The volume of distribution was 11 litres. The invasion half-life after intramuscular and subcutaneous administration was 12 and 11 minutes respectively and the elimination half-lives 1 and 1.5 hours, respectively. The bioavailability of the intramuscular and subcutaneous forms was found to be 66 and 71% respectively when areas under their plasma concentration/time curves were compared with the intravenous area.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001682:Biological Availability; D001702:Biopharmaceutics; D002116:Calcitonin / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay
D002116:Calcitonin